(Q43814680)

English

Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.

scientific article published on 11 May 2007

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17496309%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17496309%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

based on heuristic

inferred from title

B-cell lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17496309%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

T El Gnaoui

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17496309%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

J Dupuis

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17496309%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

K Belhadj

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17496309%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

J-P Jais

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17496309%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

A Rahmouni

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17496309%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

C Copie-Bergman

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17496309%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

I Gaillard

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17496309%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

M Diviné

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17496309%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

I Tabah-Fisch

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17496309%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

F Reyes

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17496309%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

publication date

11 May 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17496309%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17496309%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17496309%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17496309%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1363-1368

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17496309%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

Gemcitabine for relapsed or resistant lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

Oxaliplatin: a review of preclinical and clinical studies.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

A phase II study of gemcitabine in patients with relapsed or refractory low-grade non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

Gemcitabine and cisplatin in refractory malignant lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM133

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43814680&oldid=2103582758"